Relay Therapeutics is expected to announce Thursday that it has raised $400 million in venture capital — one of the largest hauls this year by a privately held Massachusetts biotech — to advance its drug development programs.
The Cambridge, Mass., company, which was founded in 2016 by Boston-based Third Rock Ventures, has now raised $520 million in capital.
